Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

No text entered.

Reporting Groups

Description

Triptorelin

GnRH analogue (triptorelin) during chemotherapy

no Triptorelin

no GnRH analogue (triptorelin) during chemotherapy

Total

Total of all reporting groups

Baseline Measures

Triptorelin

no Triptorelin

Total

Number of Participants
[units: participants]

27

22

49

Age
[units: participants]

<=18 years

0

0

0

Between 18 and 65 years

27

22

49

>=65 years

0

0

0

Age
[units: years]Median ( Full Range )

39
( 21 to 44 )

38
( 26 to 44 )

39
( 21 to 44 )

Gender
[units: participants]

Female

27

22

49

Male

0

0

0

Ethnicity (NIH/OMB)
[units: participants]

Hispanic or Latino

3

2

5

Not Hispanic or Latino

24

20

44

Unknown or Not Reported

0

0

0

Race (NIH/OMB)
[units: participants]

American Indian or Alaska Native

0

0

0

Asian

0

2

2

Native Hawaiian or Other Pacific Islander

0

0

0

Black or African American

2

1

3

White

25

19

44

More than one race

0

0

0

Unknown or Not Reported

0

0

0

Region of Enrollment
[units: participants]

United States

27

22

49

Outcome Measures

1. Primary:

Time to Resumption of Menses [ Time Frame: Baseline, end of chemotherapy then 5 years ]

Alternative Markers of Ovarian Failure as Assessed by Inhibin A and Inhibin B Every 6 Months Beginning in Month 6 for 2 Years and Then Annually for 3 Years [ Time Frame: Baseline, end of chemotherapy then 5 years ]

Quality of Life as Assessed by FACT-ES Monthly During Treatment, Every Very 6 Months Beginning in Month 6 for 2 Years and Then Annually for 3 Years [ Time Frame: Baseline, through chemotherapy then 5 years ]